251 related articles for article (PubMed ID: 36015197)
1. Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin
Gurel B; Berksoz M; Capkin E; Parlar A; Pala MC; Ozkan A; Capan Y; Daglikoca DE; Yuce M
Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015197
[TBL] [Abstract][Full Text] [Related]
2. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2021 Sep; 73():41-56. PubMed ID: 34593306
[TBL] [Abstract][Full Text] [Related]
3. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2022 Jun; 77():1-15. PubMed ID: 35667958
[TBL] [Abstract][Full Text] [Related]
4. Method Development and Qualification of pH-Based CEX UPLC Method for Monoclonal Antibodies.
Bhatt M; Alok A; Kulkarni BB
BioTech (Basel); 2022 Jun; 11(2):. PubMed ID: 35822792
[TBL] [Abstract][Full Text] [Related]
5. LC-MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity.
Singh SK; Kumar D; Malani H; Rathore AS
Sci Rep; 2021 Jan; 11(1):2487. PubMed ID: 33514790
[TBL] [Abstract][Full Text] [Related]
6. Fractionated charge variants of biosimilars: A review of separation methods, structural and functional analysis.
Yüce M; Sert F; Torabfam M; Parlar A; Gürel B; Çakır N; Dağlıkoca DE; Khan MA; Çapan Y
Anal Chim Acta; 2021 Apr; 1152():238189. PubMed ID: 33648647
[TBL] [Abstract][Full Text] [Related]
7. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
[TBL] [Abstract][Full Text] [Related]
8. Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat.
Zhao YY; Wang N; Liu WH; Tao WJ; Liu LL; Shen ZD
PLoS One; 2016; 11(3):e0151874. PubMed ID: 26987122
[TBL] [Abstract][Full Text] [Related]
9. Isolation and characterization of charge variants of infliximab biosimilar HS626.
Yuan JJ; Gao D; Hu F; Shi Y; Wu ZH; Hu CQ; Huang XD; Fang WJ; Zhang HT; Wang HB
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122485. PubMed ID: 33360415
[TBL] [Abstract][Full Text] [Related]
10. Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study.
Bhattacharya S; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123896. PubMed ID: 37776677
[TBL] [Abstract][Full Text] [Related]
11. Characterization of therapeutic proteins by cation exchange chromatography-mass spectrometry and top-down analysis.
Shi RL; Xiao G; Dillon TM; Ricci MS; Bondarenko PV
MAbs; 2020; 12(1):1739825. PubMed ID: 32292112
[TBL] [Abstract][Full Text] [Related]
12. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.
Xie H; Chakraborty A; Ahn J; Yu YQ; Dakshinamoorthy DP; Gilar M; Chen W; Skilton SJ; Mazzeo JR
MAbs; 2010; 2(4):379-94. PubMed ID: 20458189
[TBL] [Abstract][Full Text] [Related]
13. Charge variant analysis of proposed biosimilar to Trastuzumab.
Dakshinamurthy P; Mukunda P; Prasad Kodaganti B; Shenoy BR; Natarajan B; Maliwalave A; Halan V; Murugesan S; Maity S
Biologicals; 2017 Mar; 46():46-56. PubMed ID: 28087106
[TBL] [Abstract][Full Text] [Related]
14. High-throughput multiplex analysis of mAb aggregates and charge variants by automated two-dimensional size exclusion-cation exchange chromatography coupled to mass spectrometry.
Lambiase G; Inman SE; Muroni M; Lindo V; Dickman MJ; James DC
J Chromatogr A; 2022 May; 1670():462944. PubMed ID: 35344792
[TBL] [Abstract][Full Text] [Related]
15. C-terminal lysine clipping of IgG1: impact on binding to human FcγRIIIa and neonatal Fc receptors.
Faid V; Leblanc Y; Berger M; Seifert A; Bihoreau N; Chevreux G
Eur J Pharm Sci; 2021 Apr; 159():105730. PubMed ID: 33493670
[TBL] [Abstract][Full Text] [Related]
16. Characterization of charge variants, including post-translational modifications and proteoforms, of bispecific antigen-binding protein by cation-exchange chromatography coupled to native mass spectrometry.
Shah A; Cui W; Harrahy J; Ivanov AR
Talanta; 2024 Jan; 266(Pt 1):125062. PubMed ID: 37566926
[TBL] [Abstract][Full Text] [Related]
17. Titer and charge-based heterogeneity multiattribute monitoring of mAbs in cell culture harvest using 2D ProA CEX MS.
Sarin D; Kumar S; Rathore AS
Talanta; 2024 Aug; 276():126232. PubMed ID: 38749159
[TBL] [Abstract][Full Text] [Related]
18. An Online Two-Dimensional Approach to Characterizing the Charge-Based Heterogeneity of Recombinant Monoclonal Antibodies Using a 2D-CEX-AEX-MS Workflow.
Kumar S; Peruri V; Rathore AS
J Am Soc Mass Spectrom; 2023 Dec; 34(12):2801-2810. PubMed ID: 37994779
[TBL] [Abstract][Full Text] [Related]
19. Online Collision-Induced Unfolding of Therapeutic Monoclonal Antibody Glyco-Variants through Direct Hyphenation of Cation Exchange Chromatography with Native Ion Mobility-Mass Spectrometry.
van Schaick G; Domínguez-Vega E; Castel J; Wuhrer M; Hernandez-Alba O; Cianférani S
Anal Chem; 2023 Feb; 95(8):3932-3939. PubMed ID: 36791123
[TBL] [Abstract][Full Text] [Related]
20. Elucidation of degradants in acidic peak of cation exchange chromatography in an IgG1 monoclonal antibody formed on long-term storage in a liquid formulation.
Gandhi S; Ren D; Xiao G; Bondarenko P; Sloey C; Ricci MS; Krishnan S
Pharm Res; 2012 Jan; 29(1):209-24. PubMed ID: 21845507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
